AAAAAA

   
Results: 1-11 |
Results: 11
Multiple-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist
Authors: Dutta, S Samara, E Lam, W Granneman, GR Leese, PT Padley, RJ
Citation: S. Dutta et al., Multiple-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist, CLIN DRUG I, 21(2), 2001, pp. 129-136
Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist
Authors: Samara, E Dutta, S Cao, GL Granneman, GR Dordal, MS Padley, RJ
Citation: E. Samara et al., Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist, J CLIN PHAR, 41(4), 2001, pp. 397-403
Meta-analysis of randomized trials of terazosin in the treatment of benignprostatic hyperplasia
Authors: Boyle, P Robertson, C Manski, R Padley, RJ Roehrborn, CG
Citation: P. Boyle et al., Meta-analysis of randomized trials of terazosin in the treatment of benignprostatic hyperplasia, UROLOGY, 58(5), 2001, pp. 717-722
Proapoptotic anti-inflammatory drugs
Authors: Myers, C Koki, A Pamukcu, R Wechter, W Padley, RJ
Citation: C. Myers et al., Proapoptotic anti-inflammatory drugs, UROLOGY, 57(4A), 2001, pp. 73-76
Other novel agents: Rationale and current status as chemopreventive agents
Authors: Tolcher, AW Kennedy, A Padley, RJ Majeed, N Pollak, M Kantoff, PW
Citation: Aw. Tolcher et al., Other novel agents: Rationale and current status as chemopreventive agents, UROLOGY, 57(4A), 2001, pp. 86-89
Selective ETA receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans
Authors: Honing, MLH Hijmering, ML Ballard, DE Yang, YHP Padley, RJ Morrison, PJ Rabelink, TJ
Citation: Mlh. Honing et al., Selective ETA receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans, J AM S NEPH, 11(8), 2000, pp. 1498-1504
Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans
Authors: Verhaar, MC Grahn, AY van Weerdt, AWM Honing, MLH Morrison, PJ Yang, YHP Padley, RJ Rabelink, TJ
Citation: Mc. Verhaar et al., Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans, BR J CL PH, 49(6), 2000, pp. 562-573
Effects of endothelin receptor antagonists on the plasma immunoreactive endothelin-1 level
Authors: Opgenorth, TJ Wessale, JL Dixon, DB Adler, AL Calzadilla, SV Padley, RJ Wu-Wong, JR
Citation: Tj. Opgenorth et al., Effects of endothelin receptor antagonists on the plasma immunoreactive endothelin-1 level, J CARDIO PH, 36, 2000, pp. S292-S296
Evidence for vasoconstriction mediated by the endothelin-B receptor in domestic swine
Authors: Burke, SE Nelson, RA Lubbers, NL Ford, TT Fu, KI Padley, RJ Wegner, CD Cox, BF
Citation: Se. Burke et al., Evidence for vasoconstriction mediated by the endothelin-B receptor in domestic swine, J CARDIO PH, 35(6), 2000, pp. 838-844
ABT-627, an endothelin ETA receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain
Authors: Jarvis, MF Wessale, JL Zhu, CZ Lynch, JJ Dayton, BD Calzadilla, SV Padley, RJ Opgenorth, TJ Kowaluk, EA
Citation: Mf. Jarvis et al., ABT-627, an endothelin ETA receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain, EUR J PHARM, 388(1), 2000, pp. 29-35
Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications
Authors: Lowe, FC Olson, PJ Padley, RJ
Citation: Fc. Lowe et al., Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications, UROLOGY, 54(1), 1999, pp. 81-85
Risultati: 1-11 |